ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile

 

Gilead Sciences, Inc. 

333 Lakeside Drive

Foster City  California  94404  U.S.A.
Phone: 800-GILEAD-5 or 650-574-3000 Fax: 650-522-5800


SEARCH JOBS


Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need.The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.


 Key Statistics


Email:
Ownership: Public

Web Site: Gilead Sciences, Inc.
Employees: 4,000
Symbol: GILD
 



Industry
Biotechnology






 Company News
Gilead Sciences, Inc. (GILD)'s Harvoni Will Fast Track: Analyst 9/26/2014 2:52:15 PM
This Little Switch Could Make Gilead Sciences, Inc. (GILD) Stock Billions 9/26/2014 7:41:11 AM
Gilead Sciences, Inc. (GILD) Release: The Medicines Patent Pool Adds New Sub-Licensing Agreements To Improve Access To Novel Arvs In Developing Countries 9/25/2014 8:56:22 AM
Gilead Sciences, Inc. (GILD) Submits New Drug Application To Japan’s Pharmaceutical And Medical Devices Agency For Fixed-Dose Combination Of Ledipasvir/Sofosbuvir For Chronic Hepatitis C Genotype 1 Infection 9/24/2014 11:26:16 AM
Gilead Sciences, Inc. (GILD)'s Single Tablet HIV Regimen Meets Goals In Two Phase 3 Studies 9/24/2014 6:39:28 AM
EU Approval Of Gilead Sciences, Inc. (GILD)'s Zydelig Nothing But Good News, Says Analyst 9/19/2014 3:37:52 PM
European Commission Grants Marketing Authorization For Gilead Sciences, Inc. (GILD)’s Zydelig® (Idelalisib) For The Treatment Of Chronic Lymphocytic Leukemia And Follicular Lymphoma 9/19/2014 10:51:14 AM
60 Percent Of New York’s Hep C Patients Will Get Gilead Sciences, Inc. (GILD)'s Sovaldi 9/19/2014 6:21:22 AM
Analyst: Gilead Sciences, Inc. (GILD) Still A Buy After Cancer Drug Fail 9/17/2014 5:49:21 PM
Hetero Enters License Agreement With Gilead Sciences, Inc. (GILD), U.S.A. To Produce Generic Sofosbuvir For Treatment Of Chronic Hepatitis C 9/17/2014 9:41:26 AM
12345678910...